AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for early Parkinson’s disease (PD).

The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate to severe symptoms of uterine fibroids (UFs) in women of reproductive age. This decision means ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...